Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.

Herantis Pharma logo

Find us on LinkedIn


  • Highlight

    Invitation to Full Year 2023 results webcast on Wednesday March 6 at 9:30 am EET (8:30 CET)

  • Highlight

    Herantis Pharma announces positive topline data from the Phase 1a clinical trial of HER-096

Latest news and releases